EP3911651A1 - Process for preparing fostemsavir - Google Patents

Process for preparing fostemsavir

Info

Publication number
EP3911651A1
EP3911651A1 EP20702386.2A EP20702386A EP3911651A1 EP 3911651 A1 EP3911651 A1 EP 3911651A1 EP 20702386 A EP20702386 A EP 20702386A EP 3911651 A1 EP3911651 A1 EP 3911651A1
Authority
EP
European Patent Office
Prior art keywords
mmol
vols
added
ethyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP20702386.2A
Other languages
German (de)
French (fr)
Other versions
EP3911651B1 (en
Inventor
Antal HARSANYL
Andrew David Searle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 4 Ltd
Original Assignee
ViiV Healthcare UK No 4 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ViiV Healthcare UK No 4 Ltd filed Critical ViiV Healthcare UK No 4 Ltd
Publication of EP3911651A1 publication Critical patent/EP3911651A1/en
Application granted granted Critical
Publication of EP3911651B1 publication Critical patent/EP3911651B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a process for preparing Fostemsavir.
  • HIV infection remains a major medical problem.
  • HIV attachment inhibitors are compounds that bind to the HIV surface glycoprotein gpl20 and interfere with the interaction between the surface protein gpl20 and the host cell receptor CD4. Thus, they prevent HIV from attaching to the human CD4 T-cell and block HIV replication in the first stage of the HIV life cycle.
  • Fostemsavir One HIV attachment inhibitor compound that has shown promise as a treatment for HIV infection is Fostemsavir.
  • Fostemsavir is described, for example in US 7,745,625.
  • Methods for preparing Fostemsavir are described, for example, in the '625 patent and in
  • Fostemsavir is a prodrug of Temsavir.
  • Temsavir is described, for example, in US patent 7,354,924.
  • Methods for preparing Temsavir are described, for example, in the '924 patent and in W02007/002308.
  • P is a suitable protecting group such as mesylate, tosylate, or besylate.
  • the present invention discloses a method for preparation of a compound of Formula IV
  • P 1 is H or a suitable protecting group
  • P 2 is H or a suitable protecting group and R 1 is H or C1-6alkyl.
  • Compounds of Formula IV can be converted to Temsavir, Fostemsavir, and various salts thereof using known methods, for examples those referenced in the Background section.
  • the method of this invention further comprises the conversion of a compound of Formula I to a compound of Formula II
  • each P 2 is independently H or a suitable protecting group.
  • the method of this invention further comprises the conversion of a compound of Formula II into a compound of Formula III
  • each P 1 and P 2 are independently H or a suitable protecting group.
  • Protecting groups are well known in the art and a chemist skilled in the art would be able to choose appropriate protecting groups.
  • P 1 is H or a sulphonyl group. More preferably P 1 is H or a mesylate, besylate, or tosylate group.
  • P 2 is H or an alkyloxycarbonyl, aryloxycarbonyl, acetyl optionally substituted with 1-3 halogens, sulphonyl, alkyl, C 1-6 alkyl, or benzyl group. More preferably P 2 is H or - C(0)-0-C1-4alkyl, -C(0)-C1-4alkyl, -C(0)-C1-4haloalkyl, mesylate, besylate, tosylate, C1-6alkyl, or -C1- 6 alkyl-aryl.
  • a compound of Formula 1 can be prepared from furfurylamine and a protected chloroacetate (for example, ethyl chloroacetate) in the presence of a suitable base followed by protection with a suitable reagent (for example, ethyl chloroformate) in the presence of a suitable base (for example, triethylamine).
  • a compound of Formula I can be converted to a compound of Formula II by hydrolysis in the presence of a suitable base (for example, potassium hydroxide), followed by formation of an acid chloride which can be cyclised using a suitable catalyst (for example, Aluminium Chloride).
  • a compound of Formula II can be converted to a compound of Formula III by reaction with ammonia or an ammonia eqvuivalent in the presence of a secondary amine reagent, for example pyrrolidine followed by protection with a suitable reagent (for example, benzenesulfonyl chloride or 4-methylbenzenesulfonyl chloride) in the presence of a suitable base (for example, triethylamine).
  • a suitable reagent for example, benzenesulfonyl chloride or 4-methylbenzenesulfonyl chloride
  • a suitable base for example, triethylamine
  • a compound of Formula III can be converted to a compound of Formula IV by conversion to the corresponding methyl enol ether and oxidation with a suitable reagent (for example, Cumene Hydroperoxide or tert-butyl hydroperoxide.
  • Furfurylamine (1) (5.50 mL, 51.5 mmol) and triethylamine (7.90 mL, 56.5 mmol, 1.1 eqv) were dissolved in toluene (27.5 mL, 5 vols.).
  • Ethyl chloroacetate (2) (6.05 mL, 56.5 mmol, 1.1 eqv) was added and the mixture was heated to 115 °C for 3 hours. Reaction was then cooled to 20°C, water (33 mL, 6 vols.) was added and the mixture was extracted with ethyl acetate (3x 27.5 mL, 3x5 vols.).
  • the reaction mixture was poured over ice water (120 mL, 30 vols.), the organic layer was separated, washed with water (2x 40 mL, 2x 10 vols) and a saturated brine solution (lx 40 mL, 10 vols.), dried over anhydrous magnesium sulphate, filtered and the solvent evaporated in vacuo.
  • the residue was dissolved in ethyl acetate (40 mL, 10 vols.), washed with 5% aqueous ammonia (lx 20 mL, 5 vols.) and then water (3x 20 mL, 2x 5 vols) and the solvent evaporated in vacuo.
  • Step 5 Preparation of ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)- carboxylate (7)
  • Step 6 Preparation of ethyl 4-oxo-l-(phenylsulfonyl)-4,5-dihydro-lH-pyrrolo[2,3- c]pyridine-6(7H)-carboxylate (8)
  • reaction mixture was stirred until benzene sulphonyl chloride was consumed.
  • the mixture was poured into water (10 mL, 20 vols.) and extracted with methylene chloride (2x 5 mL, 10 vols. each). Combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo.
  • Triethylamine (0.506 mL, 3.6 mmol, 2.5 eqv) was added at a rate to maintain the internal temperature at £30 °C, and pH was confirmed in range 8-9.
  • 1 wt% aqueous sodium thiosulphate solution (2 mL, 4 vols.) was added and the batch aged for 1 hour.
  • 1 wt% aqueous sodium thiosulphate solution (8 mL, 16 vols.) was added over 30 minutes. The batch was aged for 1 hour, and the pH was confirmed as >8.
  • Methylene chloride (15 mL, 30 vols.) was added to the reaction mixture, and the layers were separated.
  • the aqueous layer was washed with methylene chloride (2x 5 mL, 2x 10 vols.) and the combined organic layers were washed with 1M sodium hydroxide (2x 5 mL, 2x 10 vols) and water (lx 5 mL, 10 vols).
  • the combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo to leave a brown oil which was purified by column chromatography (12-100% gradient ethyl acetate in hexane) to give 4-methoxy-l-(phenylsulfonyl)-lH-pyrrolo[2,3-c]pyridine (9) as a yellow solid (0.345 g, 1.20 mmol, 83.0% yield).
  • Steps 1-7 are the same as for Example 1
  • Step 8 Preparation of ethyl 4-oxo-l-tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine- 6(7H)-carboxylate (10)
  • reaction mixture was stirred until p-toluenesulphonyl chloride was consumed.
  • the mixture was poured into water (10 mL, 20 vols.) and extracted with methylene chloride (2x 5 mL, 2x 10 vols.). Combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo.
  • Triethylamine (0.485 mL, 3.45 mmol, 2.5 eqv) was added at a rate to maintain the internal temperature at £30 °C, and pH was confirmed in range 8-9.
  • 1 wt% aqueous sodium thiosulphate solution (2 mL, 4 vols.) was added and the batch aged for 1 hour.
  • 1 wt% aqueous sodium thiosulphate solution (8 mL, 16 vols.) was added over 30 minutes. The batch was aged for 1 hour, and the pH was confirmed as >8.
  • Methylene chloride (15 mL, 30 vols.) was added to the reaction mixture, and the layers were separated.
  • the aqueous layer was washed with methylene chloride (2x 5 mL, 2x 10 vols.) and the combined organic layers were washed with water (2x 5 mL, 2x 5 vols) and saturated brine solution (2x 25 mL, 2x 5 vols).
  • Furfurylamine (1) (lOOg, 1.03 mol) and triethylamine (430 mL, 3.09 mol, 3.0 eqw) were dissolved in toluene (670ml, 6.7 vols.).
  • Ethyl chloroacetate (2) (126 mL, 1.18 mol, 1.15 eqv) was added and the mixture was heated to 65 °C for 26 hours. The reaction mixture was cooled to 20°C, and filtered, then the precipitated solids were washed with toluene (200ml, 2vol).
  • Step 4 An alternative preparation of Step 4 where aqueous potassium hydroxide is used in the work-up and material isolated by crystallisation is shown below:
  • methylene chloride 400 mL, 20 vols.
  • aluminium chloride 25.23 g, 189 mmol, 2.15 eqw
  • the acid chloride solution prepared above was slowly added to the aluminium chloride mixture over 1 hour.
  • aluminium chloride (1.17g. 8.8 mmol, 0.1 eqw) was added and stirring maintained at 0°C for a further 30 minutes.
  • 50% potassium hydroxide solution (89g) was added slowly then the reaction warmed to 38°C and stirred for 15h.
  • Step 5 An alternative preparation of Step 5 where pyrrolidine is used as a solvent and the reaction is run at ambient temperature as a result is presented below:
  • Step 5 Preparation of ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)- carboxylate (7)
  • Step 8 is the same as for Example 2.
  • Step 8 Preparation of ethyl 4-oxo-l-tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine- 6(7H)-carboxylate (10)
  • reaction mixture was stirred until p-toluenesulphonyl chloride was consumed.
  • the mixture was poured into water (10 mL, 20 vols.) and extracted with methylene chloride (2x 5 mL, 2x 10 vols.) ⁇ Combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo.
  • Step 9 An alternative preparation of Step 9 where tert-butyl hydroperoxide in decane is used as an oxidant is presented below:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Furan Compounds (AREA)

Abstract

A method for the preparation of a compound of Formula IV wherein P1 is H or a suitable protecting group, comprising preparation of a compound of Formula I wherein P2 is H or a suitable protecting group and R1 is H or C1-6alkyl.

Description

PROCESS FOR PREPARING FOSTEMSAVIR
FIELD OF THE INVENTION
The present invention relates to a process for preparing Fostemsavir.
BACKGROUND OF THE INVENTION
HIV infection remains a major medical problem. One class of compounds with potential for treating HIV infection are HIV attachment inhibitors. These are compounds that bind to the HIV surface glycoprotein gpl20 and interfere with the interaction between the surface protein gpl20 and the host cell receptor CD4. Thus, they prevent HIV from attaching to the human CD4 T-cell and block HIV replication in the first stage of the HIV life cycle.
One HIV attachment inhibitor compound that has shown promise as a treatment for HIV infection is Fostemsavir. Fostemsavir is described, for example in US 7,745,625. Methods for preparing Fostemsavir are described, for example, in the '625 patent and in
W02012/106189, WO2013/119625, and W02016/100633.
Fostemsavir is a prodrug of Temsavir. Temsavir is described, for example, in US patent 7,354,924. Methods for preparing Temsavir are described, for example, in the '924 patent and in W02007/002308.
An intermediate in the preparation of Temsavir and Fostemsavir is the following compound
where P is a suitable protecting group such as mesylate, tosylate, or besylate.
SUMMARY OF THE INVENTION
Briefly, in one aspect, the present invention discloses a method for preparation of a compound of Formula IV
wherein P1 is H or a suitable protecting group;
comprising the preparation of a compound of Formula I
wherein P2 is H or a suitable protecting group and R1 is H or C1-6alkyl.
Compounds of Formula IV can be converted to Temsavir, Fostemsavir, and various salts thereof using known methods, for examples those referenced in the Background section.
DETAILED DESCRIPTION OF THE INVENTION
Preferably, the method of this invention further comprises the conversion of a compound of Formula I to a compound of Formula II
wherein each P2 is independently H or a suitable protecting group.
Preferably, the method of this invention further comprises the conversion of a compound of Formula II into a compound of Formula III
wherein each P1 and P2 are independently H or a suitable protecting group.
Protecting groups are well known in the art and a chemist skilled in the art would be able to choose appropriate protecting groups.
Preferably P1 is H or a sulphonyl group. More preferably P1 is H or a mesylate, besylate, or tosylate group.
Preferably P2 is H or an alkyloxycarbonyl, aryloxycarbonyl, acetyl optionally substituted with 1-3 halogens, sulphonyl, alkyl, C1-6alkyl, or benzyl group. More preferably P2 is H or - C(0)-0-C1-4alkyl, -C(0)-C1-4alkyl, -C(0)-C1-4haloalkyl, mesylate, besylate, tosylate, C1-6alkyl, or -C1-6alkyl-aryl.
EXAMPLES
One embodiment of the method of this invention can be summarized by the following reaction scheme.
The method of this invention is further illustrated by the following examples. Examples 1, 2 and 3 are summarized in the three schemes below:
Example 1
Example 2
Example 3
As a general summary of an embodiment of the method of this invention, a compound of Formula 1 can be prepared from furfurylamine and a protected chloroacetate (for example, ethyl chloroacetate) in the presence of a suitable base followed by protection with a suitable reagent (for example, ethyl chloroformate) in the presence of a suitable base (for example, triethylamine). A compound of Formula I can be converted to a compound of Formula II by hydrolysis in the presence of a suitable base (for example, potassium hydroxide), followed by formation of an acid chloride which can be cyclised using a suitable catalyst (for example, Aluminium Chloride). A compound of Formula II can be converted to a compound of Formula III by reaction with ammonia or an ammonia eqvuivalent in the presence of a secondary amine reagent, for example pyrrolidine followed by protection with a suitable reagent (for example, benzenesulfonyl chloride or 4-methylbenzenesulfonyl chloride) in the presence of a suitable base (for example, triethylamine). A compound of Formula III can be converted to a compound of Formula IV by conversion to the corresponding methyl enol ether and oxidation with a suitable reagent (for example, Cumene Hydroperoxide or tert-butyl hydroperoxide.
EXAMPLE 1:
Step 1: Preparation of ethyl 2-((furan-2-ylmethyl)amino)acetate (3)
Furfurylamine (1) (5.50 mL, 51.5 mmol) and triethylamine (7.90 mL, 56.5 mmol, 1.1 eqv) were dissolved in toluene (27.5 mL, 5 vols.). Ethyl chloroacetate (2) (6.05 mL, 56.5 mmol, 1.1 eqv) was added and the mixture was heated to 115 °C for 3 hours. Reaction was then cooled to 20°C, water (33 mL, 6 vols.) was added and the mixture was extracted with ethyl acetate (3x 27.5 mL, 3x5 vols.). The organic layer was washed with water (2x 27.5 mL, 2x 5 vols.) and a saturated brine solution of (27.5 mL, 5 vols.), then dried over anhydrous magnesium sulphate, filtered and the solvent was evaporated in vacuo to give ethyl 2-((furan- 2-ylmethyl)amino)acetate (3) as a yellow liquid (7.15 g, 42.8 mmol, 75.8% yield). 1H NMR (600 MHz, DMSO-d6, 300K): d 7.55 (1H, dd, J = 1.8 Hz, 0.9 Hz), 6.34 (1H, dd, J = 3.1 Hz, 1.8 Hz), 6.22 (1H, dd, J = 3.1 Hz, 0.9 Hz), 4.08 (2H, q, J = 7.2 Hz), 3.70, (2H, s), 3.29 (2H, s), 1.19 (3H, t, J = 7.2 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 172.4, 154.2, 142.4, 110.7, 107.4, 60.4, 49.7, 45.1, 14.6. HRMS (ESI) m/z [M+H}+: molecular ion calculated for C9H14NO3: 184.0968, found 184.0974, error 3.4 ppm. (3) can be further purified by column chromatography - normal phase on silica gel, 0-20% gradient of methanol in methylene chloride.
Ethyl 2-((furan-2-ylmethyl)amino)acetate(3) (5.00 g, 27.3 mmol) and triethylamine (4.55 mL, 32.8 mmol, 1.2 eqv) were dissolved in methylene chloride (5 mL, 1 vol.). Ethyl chloroformate (2.24 mL, 32.8 mmol, 1.2 eqv) was added dropwise at 0 °C (reaction temperature NGT 25 °C) and the mixture was stirred at 20°C for 3 hours. Water (25 mL, 5 vols.) was added and the mixture was extracted with methylene chloride (2x 25 mL, 2x 5 vols.)· The organic layer was washed with water (2x 25 mL, 2x 5 vols.) and a saturated brine (lx 25 mL, 5 vols.), dried over anhydrous magnesium sulphate, filtered and the solvent was evaporated in vacuoto leave ethyl 2-((ethoxycarbonyl)(furan-2-ylmethyl)amino)acetate (4) as a dark brown oil (6.41 g, 25.14 mmol, 92.1% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately eqvual ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.60-7.58 (A+B, 1H, m), 6.40-6.38, (A+B, 1H, m), 6.36 (A, 1H, d, J = 3.2 Hz), 6.33 (B, 1H, d, J = 3.2 Hz), 4.46 (A+B, 2H, s), 4.09 (B, 2H, q, J = 7.0 Hz)), 4.08, (A+B, 2H, q, J = 7.7 Hz), 4.04, (A, 2H, q, J = 7.0 Hz) 3.94,
(A+B, 2H, s), 1.20 (B, 3H, t, J = 7.0 Hz), 1.17 (A+B, 3H, t, J = 7.1 Hz), 1.13 (B, 3H, t, J = 7.0Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 169.7 (A), 169.6 (B), 159.9 (B), 155.8 (A), 151.1 (B), 151.0 (A), 143.3 (A), 143.2 (B), 110.9 (B), 110.8 (A), 109.1 (A), 108.8 (B), 61.8 (B), 61.6 (A), 61.03 (A), 60.98 (B), 48.5 (B), 48.2 (A), 44.3 (A), 44.2 (B), 14.90 (B), 14.85
(A), 14.5 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for CizHisNOs: 256.1179, found 256.1184, error 1.9 ppm. (4) can be further purified by column chromatography - normal phase on silica gel, 0-60% gradient of ethyl acetate in hexane.
Step 3: Preparation of 2-((ethoxycarbonyl)(furan-2-ylmethyl)amino)acetic acid (5)
Ethyl 2-((ethoxycarbonyl)(furan-2-ylmethyl)amino)acetate (4) (5.00 g, 19.6 mmol) was dissolved in methanol (25ml, 5 vols.), potassium hydroxide (1.65 g, 29.4 mmol, 1.5 eqv) was added and the mixture was heated at 65 °C for 3 hours. The solvent was evaporated in vacuo and the residue was dissolved in methylene chloride (50 mL, 10 vols.). The resulting solution was slowly neutralized with 1 N aqueous solution of hydrochloric acid with stirring to adjust to pH 3. The organic layer was separated, washed with water (2x 25 mL, 2x 5 vols.) and a saturated brine solution of (lx 25 mL, 5 vols.), dried over anhydrous magnesium sulphate, filtered and the solvent evaporated in vacuo to leave 2-((ethoxycarbonyl)(furan-2- ylmethyl)amino)acetic acid (5) as a dark brown oil (4.23 g, 18.6 mmol, 95.1% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately equal ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.60-7.58 (A+B, 1H, m), 6.40-6.38, (A+B, 1H, m), 6.36 (A, 1H, d, J = 3.0 Hz), 6.34 (B, 1H, d, J = 3.0 Hz), 4.44 (A+B, 2H, s), 4.08 (B, 2H, q, J = 7.0 Hz), 4.03, (A, 2H, q, J = 7.0 Hz) 3.83 (B, 2H, s), 3.82 (A, 2H, s), 1.20 (B, 3H, t, J = 7.0 Hz), 1.14 (A, 3H, t, J = 7.0Hz).
13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 171.1 (A), 171.0 (B), 156.0 (A), 155.9 (B), 151.2
(B), 151.1 (A), 143.3 (A), 143.2 (B), 110.91 (B), 110.88 (A), 109.1 (A), 108.8 (B), 61.7 (B), 61.6 (A), 61.03 (A), 48.3 (B), 47.9 (A), 44.2 (A), 44.1 (B), 14.94 (B), 14.91 (A). HRMS (ESI) m/z [M+Na}+: molecular ion calculated for CioHi3NNaO5: 250.0686, found 250.0681, error 1.9 ppm. (5) can be further purified by column chromatography - normal phase on silica gel, 0- 20% gradient of methanol in methylene chloride.
Step 4: Preparation of ethyl 4-oxo-4,5-dihydrofuro[2,3-c]pyridine-6(7H)- carboxylate (6)
2-((Ethoxycarbonyl)(furan-2-ylmethyl)amino)acetic acid (5) (4.00 g, 17.6 mmol) was dissolved in methylene chloride (60 mL, 15 vols.), thionyl chloride (1.92 mL, 26.4 mmol, 1.5 eqv) and dimethylformamide (0.014 mL, 0.18 mmol, 0.01 eqv) were added and the mixture was heated at 50 °C for 3 hours. The reaction was cooled and diluted with methylene chloride (120 mL, 30 vols.), and aluminium chloride (4.69 g, 35.2 mmol, 2 eqv) was added. The mixture was stirred at 20°C for 1 hour. The reaction mixture was poured over ice water (120 mL, 30 vols.), the organic layer was separated, washed with water (2x 40 mL, 2x 10 vols) and a saturated brine solution (lx 40 mL, 10 vols.), dried over anhydrous magnesium sulphate, filtered and the solvent evaporated in vacuo. The residue was dissolved in ethyl acetate (40 mL, 10 vols.), washed with 5% aqueous ammonia (lx 20 mL, 5 vols.) and then water (3x 20 mL, 2x 5 vols) and the solvent evaporated in vacuo. The residue solidified to give ethyl 4-oxo- 4,5-dihydrofuro[2,3-c]pyridine-6(7H)-carboxylate (6) as yellow/orange solid (2.14 g, 10.2 mmol, 58.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately eqvual ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.86 (A+B, 1H, d, J = 2.0 Hz), 6.80 (A+B, 1H, d, J = 2.0 Hz), 4.81 (A+B, 2H, br s), 4.17 (A+B, 2H, br s), 4.11 (A+B, 2H, q, J = 7.1 Hz), 1.21 (A+B, 3H, t, J = 7.1 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 188.3 (A+B), 163.7 (A), 163.4 (B), 154.6 (A+B), 144.9 (A+B), 119.1 (A+B), 105.9 (A+B), 61.8 (A+B), 51.7 (A), 51.5 (B), 41.3 (A+B), 14.4 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for C10H12NO4:
210.0761, found 210.0767, error 3.0 ppm.
Step 5: Preparation of ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)- carboxylate (7)
Ethyl 4-oxo-4,5-dihydrofuro[2,3-c]pyridine-6(7H)-carboxylate (6) (2.00 g, 9.55 mmol) was dissolved in ethanol (10 mL, 5 vols.) and transferred to pressure vessel. 25% aq.
ammonia (10 mL, 5 vols.) was added, the vessel was sealed, heated to 100 °C (reaction temperature 95 °C) and stirred for 8 hours. The ethanol was removed in vacuo and methylene chloride (10 mL, 5 vols.) was added to the residue. A black precipiate was filtered off and the filtrate was evaporated in vacuo, to leave ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine- 6(7H)-carboxylate (7) as a dark brown oil (1.77 g, 8.50 mmol, 89.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately eqvual ratio are visible. They are due to restricted rotation of the tertiary amide: d 11.58 (A, 1H, s), 11.53 (B, 1H, s), 6.87-6.88 (A+B, 1H, m), 6.36 (A+B, 1H, dd, J = 2.2 Hz, 2.8 Hz), 4.70 (A+B, 2H, br s), 4.09 (A+B, 2H, q, J = 7.1 Hz), 4.06 (A+B, 2H, br s), 1.20 (A+B, 3H, t, J =
7.1 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 188.0 (A), 187.8 (B), 155.2 (A), 155.1 (B), 140.9 (A), 140.5 (B), 120.8 (A+B), 118.2 (A), 118.0 (B), 104.9 (A+B), 61.9 (A+B), 52.2 (A), 52.0 (B), 41.1 (A), 41.0 (B), 14.9 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for C10H13N2O3: 209.0921, found 209.0929, error 3.9 ppm. (7) may be further purified by column chromatography - normal phase on silica gel, 12-100% gradient of ethyl acetate in hexane.
Step 6: Preparation of ethyl 4-oxo-l-(phenylsulfonyl)-4,5-dihydro-lH-pyrrolo[2,3- c]pyridine-6(7H)-carboxylate (8)
To a solution of (ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate) (7) (0.50 g, 2.4 mmol) in methylene chloride (5 mL, 10 vols.) was added triethylamine (0.97 mL, 7.2 mmol, 3 eqv.) dropwise at 20°C. To the resulting suspension was added benzene sulphonyl chloride (0.306 mL, 2.4 mmol, 1 eqv) and 4-dimethylaminopyridine (DMAP) (0.029 g, 0.24 mmol, 0.1 eqv). The reaction mixture was stirred until benzene sulphonyl chloride was consumed. The mixture was poured into water (10 mL, 20 vols.) and extracted with methylene chloride (2x 5 mL, 10 vols. each). Combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo. The crude was purified by flash chromatography on silica gel (12-100% gradient ethyl acetate in hexane) affording ethyl 4-oxo-l-(phenylsulfonyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate (8) as a yellow semi-solid (0.56 g, 1.61 mmol, 67.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately eqvual ratio are visible. They are due to restricted rotation of the tertiary amide: d 8.08 (A+B, 2H, d, J = 8.0 Hz), 7.86 (A+B, 1H, t, J = 8.0 Hz), 7.74 (A+B, 2H, t, J = 8.0 Hz), 7.58 (A+B, 1H, d, J = 3.2 Hz), 6.66 (A+B, 1H, d, J = 3.2 Hz), 4.99 (A+B, 2H, s), 4.16 (A+B, 2H, br s), 4.06 (A+B, 2H br q, J =
7.0 Hz), 1.17 (A+B, 3H, br t, J = 7.0 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 189.1 (A), 188.7 (B), 155.2 (A), 155.0 (B), 141.3 (A), 140.9 (B), 137.3 (A+B), 136.2 (A+B), 130.9 (A+B), 127.6 (A+B), 123.8 (A+B), 122.9 (A), 122.7 (B), 109.0 (A+B), 62.3 (A+B), 52.0 (A+B), 41.7 (A), 41.3 (B), 14.9 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for C16H17N2O5S: 349.0853, found 349.0857, error 1.1 ppm. Step 7: Preparation of 4-methoxy-l-(phenylsulfonyl)-lH-pyrrolo[2,3-c]pyridine (9)
Ethyl 4-oxo-l-(phenylsulfonyl)-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)- carboxylate (8) (0.50 g, 1.44 mmol) was charged to reaction vessel and vessel was inerted using N2. Methanol (6 mL, 12 vols.), methane sulphonic acid (0.109 mL, 2.16 mmol, 1.5 eqv,) and trimethylorthoformate (0.788 mL, 7.2 mmol, 5 eqv) were added and reaction mixture was heated to 30-35 °C and aged for 2 hours. 80% Cumene hydroperoxide (CHP) (0.064 mL,
0.345 mmol, 0.25 eqv) was added and the reaction mixture was aged at 30-35 °C for 2-3 hours. Another 80% CHP (0.067 mL, 0.36 mmol, 0.25 eqv) was added and the reaction mixture was aged at 30-35 °C for 2-3 hours. A further charge of 80% CHP (0.067 mL, 0.36 mmol, 0.25 eqv), was added, the reaction was aged for 1 hour. This was repeated as reqvuired until reaction went to completion. The mixture was cooled to 20 °C. Triethylamine (0.506 mL, 3.6 mmol, 2.5 eqv) was added at a rate to maintain the internal temperature at £30 °C, and pH was confirmed in range 8-9. 1 wt% aqueous sodium thiosulphate solution (2 mL, 4 vols.) was added and the batch aged for 1 hour. 1 wt% aqueous sodium thiosulphate solution (8 mL, 16 vols.) was added over 30 minutes. The batch was aged for 1 hour, and the pH was confirmed as >8. Methylene chloride (15 mL, 30 vols.) was added to the reaction mixture, and the layers were separated. The aqueous layer was washed with methylene chloride (2x 5 mL, 2x 10 vols.) and the combined organic layers were washed with 1M sodium hydroxide (2x 5 mL, 2x 10 vols) and water (lx 5 mL, 10 vols). The combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo to leave a brown oil which was purified by column chromatography (12-100% gradient ethyl acetate in hexane) to give 4-methoxy-l-(phenylsulfonyl)-lH-pyrrolo[2,3-c]pyridine (9) as a yellow solid (0.345 g, 1.20 mmol, 83.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K): d 8.89 (1H, s), 8.12 (1H, s), 8.06-8.09 (2H, m), 7.97 (1H, d, J = 3.7 Hz), 7.73 (1H, tt, J = 7.5 Hz, 1.1 Hz), 7.64- 7.61 (2H, m), 6.90 (1H, d, J = 3.7 Hz), 3.96 (3H, s). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 149.2, 137.2, 135.6, 132.4, 130.5, 129.5, 128.8, 127.4, 126.3, 125.6. 105.9, 56.7. HRMS (ESI) m/z [M+H}+: molecular ion calculated for C14H13N2O3S: 289.0641, found 289.0644, error 1.0 ppm.
Example 2:
Steps 1-7 are the same as for Example 1
Step 8: Preparation of ethyl 4-oxo-l-tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine- 6(7H)-carboxylate (10)
To a solution of (ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate) (7) (0.50 g, 2.4 mmol) in methylene chloride (5 mL, 10 vols.) was added triethylamine (0.97 mL, 7.2 mmol, 3 eqv) dropwise at room temperature. To the resulting suspension was added p-toluenesulphonyl chloride (0.46 g, 2.4 mmol, 1 eqv) and 4-dimethylaminopyridine (DMAP) (0.029 g, 0.24 mmol, 0.1 eqv). The reaction mixture was stirred until p-toluenesulphonyl chloride was consumed. The mixture was poured into water (10 mL, 20 vols.) and extracted with methylene chloride (2x 5 mL, 2x 10 vols.). Combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo. The crude was purified by flash chromatography on silica gel (10% ethyl acetate in cyclohexane) affording ethyl 4-oxo-l- tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate (10) as a pale pink solid (0.58 g, 2.0 mmol, 83.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately equal ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.96 (A+B, 2H, d, J = 8.3 Hz), 7.55-7.53 (A+B, 3H, m), 6.64 (A+B, 1H, d, J = 3.5 Hz), 4.98 (A+B, 2H, s), 4.13 (A+B, 2H, br s), 4.07 (A+B, 2H br q, J =
7.0 Hz), 2.42 (3H, s), 1.17 (A+B, 3H, br t, J = 7.0 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 189.1 (A), 188.6 (B), 155.2 (A), 155.0 (B), 147.3 (A+B), 141.1 (A), 140.7 (B), 134.3 (A+B), 131.1 (A+B), 127.7 (A+B), 123.9 (A+B), 122.8 (A), 122.6 (B), 108.8 (A+B), 62.3 (A+B), 51.9 (A+B), 41.6 (A), 41.4 (B), 21.6 (A+B), 14.8 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for C17H19N2O5S: 363.1009, found 363.1017, error 2.2 ppm.
Step 9: Preparation of 4-methoxy-l-(4-methylphenylsulphonyl)-lH-pyrrolo[2,3- c]pyridine (11)
(Ethyl 4-oxo-l-tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate) (10) (0.50 g, 1.38 mmol) was charged to reaction vessel and vessel was inerted using N2.
Methanol (6 mL, 12 vols.), methane sulphonic acid (0.104 mL, 1.60 mmol, 1.15 eqv,) and trimethylorthoformate (0.755 mL, 6.9 mmol, 5 eqv) were added and reaction mixture was heated to 30-35 °C and aged for 2 hours. 80% Cumene hydroperoxide (CHP) (0.064 mL,
0.345 mmol, 0.25 eqv) was added and the reaction mixture was aged at 30-35 °C for 2-3 hours. Another 80% CHP (0.064 mL, 0.345 mmol, 0.25 eqv) was added and the reaction mixture was aged at 30-35 °C for 2-3 hours. A further charge of 80% CHP (0.064 mL, 0.345 mmol, 0.25 eqv), was added, the reaction was aged for 1 hour. This was repeated as reqvuired until reaction went to completion. The mixture was cooled to 20 °C. Triethylamine (0.485 mL, 3.45 mmol, 2.5 eqv) was added at a rate to maintain the internal temperature at £30 °C, and pH was confirmed in range 8-9. 1 wt% aqueous sodium thiosulphate solution (2 mL, 4 vols.) was added and the batch aged for 1 hour. 1 wt% aqueous sodium thiosulphate solution (8 mL, 16 vols.) was added over 30 minutes. The batch was aged for 1 hour, and the pH was confirmed as >8. Methylene chloride (15 mL, 30 vols.) was added to the reaction mixture, and the layers were separated. The aqueous layer was washed with methylene chloride (2x 5 mL, 2x 10 vols.) and the combined organic layers were washed with water (2x 5 mL, 2x 5 vols) and saturated brine solution (2x 25 mL, 2x 5 vols). The combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuoto leave a brown oil which was purified by column chromatography (12-100% gradient ethyl acetate in hexane) to give 4-methoxy-l-(4-methylphenylsulphonyl)-lH-pyrrolo[2,3-c]pyridine (11) as a yellow solid (0.367 g, 1.21 mmol, 88.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K): d 8.88 (1H, br s), 8.12 (1H, br s), 8.06-8.09 (2H, m), 7.96-7.93 (3H, m), 7.41 (2H, d, J = 8.3 Hz), 6.89 (1H, d, J = 3.6 Hz), 3.96 (3H, s), 2.33 (3H, s). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 149.2, 146.5, 134.2, 132.5, 130.9, 129.5, 128.8, 127.4, 126.2, 125.5, 105.8, 56.6, 21.5. HRMS (ESI) m/z [M+H}+: molecular ion calculated for C15H15N2O3S:
303.0798, found 303.0808, error 3.2 ppm.
Example 3:
An alternative preparation of Steps 1-3 where the isolation of the Step 1 and 2 intermediates is avoided is shown below:-
Steps 1-3: Preparation of 2-((ethoxycarbonyl)(furan-2-ylmethyl)amino)acetic acid (5)
Furfurylamine (1) (lOOg, 1.03 mol) and triethylamine (430 mL, 3.09 mol, 3.0 eqw) were dissolved in toluene (670ml, 6.7 vols.). Ethyl chloroacetate (2) (126 mL, 1.18 mol, 1.15 eqv) was added and the mixture was heated to 65 °C for 26 hours. The reaction mixture was cooled to 20°C, and filtered, then the precipitated solids were washed with toluene (200ml, 2vol).
To the combined filtrates, triethylamine (100 mL, 0.72 mol, 0.70 eqw) was added and the mixture cooled to 5°C. Ethyl chloroformate (111.7g, 1.03 mol, 1.0 eqw) was added dropwise (reaction temperature maintained below 15 °C) then mixture was stirred at 25°C for 8 hours. The mixture was filtered and the precipitated solids were washed with toluene (300ml, 3vol).
The combined filtrates were cooled down to 10°C and 2M aqueous potassium hydroxide (566ml, 5.66vol) was slowly added. The biphasic solution was stirred at 25°C for 48 hours The phases were separated and the organic layer was washed with water (200ml, 2vol). The combined aqueous phases were then cooled down to 5°C. 37% hydrochloric acid (lOlg) was added slowly to a final pH in the range 2-3. The mixture was extracted with tert-butyl- methylether (3 x 600ml, 3 x 6vol) The combined organic layers were dried over MgS04, filtered and evaporated to afford 2-((ethoxycarbonyl)(furan-2-ylmethyl)amino)acetic acid (5) (153g) as a brown oil. 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately equal ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.60-7.58 (A+B, 1H, m), 6.40-6.38, (A+B, 1H, m), 6.36 (A, 1H, d, J = 3.0 Hz), 6.34 (B, 1H, d, J = 3.0 Hz), 4.44 (A+B, 2H, s), 4.08 (B, 2H, q, J = 7.0 Hz), 4.03, (A, 2H, q, J = 7.0 Hz) 3.83 (B, 2H, s), 3.82 (A, 2H, s), 1.20 (B, 3H, t, J = 7.0 Hz), 1.14 (A, 3H, t, J = 7.0Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 171.1 (A), 171.0 (B), 156.0 (A), 155.9 (B), 151.2 (B), 151.1 (A), 143.3 (A), 143.2 (B), 110.91 (B), 110.88 (A), 109.1 (A), 108.8 (B), 61.7 (B), 61.6 (A), 61.03 (A), 48.3 (B), 47.9 (A), 44.2 (A), 44.1 (B), 14.94 (B), 14.91 (A). HRMS (ESI) m/z [M+Na}+: molecular ion calculated for CioHi3NNaO5: 250.0686, found 250.0681, error 1.9 ppm.
An alternative preparation of Step 4 where aqueous potassium hydroxide is used in the work-up and material isolated by crystallisation is shown below:
Step 4: Preparation of ethyl 4-oxo-4,5-dihydrofuro[2,3-c]pyridine-6(7H)- carboxylate (6)
2-((Ethoxycarbonyl)(furan-2-ylmethyl)amino)acetic acid (5) (20.0 g, 88 mmol) was dissolved in methylene chloride (200 mL, 10 vols.). Thionyl chloride (7.66 mL, 105 mmol,
1.19 eqw) and dimethylformamide (0.1 mL, 1.28 mmol, 0.015 eqw) were added and the mixture was heated at 40 °C for 1 hour then the reaction mixture was cooled to 0°C.
Separately, methylene chloride (400 mL, 20 vols.), and aluminium chloride (25.23 g, 189 mmol, 2.15 eqw) were mixed and heated to reflux for 1 hour then cooled to 0°C. The acid chloride solution prepared above was slowly added to the aluminium chloride mixture over 1 hour. After stirring for 2 hours at 0°C, aluminium chloride (1.17g. 8.8 mmol, 0.1 eqw) was added and stirring maintained at 0°C for a further 30 minutes. 50% potassium hydroxide solution (89g) was added slowly then the reaction warmed to 38°C and stirred for 15h. The reaction mixture was then filtered to remove solids, then the filtrate was dried over MgS04, then the solvent was evaporated in vacuo to give crude ethyl 4-oxo-4,5-dihydrofuro[2,3- c]pyridine-6(7H)-carboxylate (6) (14g). A portion of the crude material (6.5g) was dissolved in isopropanol (6.5ml, lvol) at 80°C, followed by addition of water (30ml, 4.62vol), then the mixture cooled to 0°C. After stirring for lh, the precipitate was filtered, washed with water (30ml, 4.62volthen dried in vacuo to give ethyl 4-oxo-4,5-dihydrofuro[2,3-c]pyridine-6(7H)- carboxylate (6) (6g) as an orange solid. ). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately equal ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.86 (A+B, 1H, d, J = 2.0 Hz), 6.80 (A+B, 1H, d, J = 2.0 Hz), 4.81 (A+B, 2H, br s), 4.17 (A+B, 2H, br s), 4.11 (A+B, 2H, q, J = 7.1 Hz), 1.21 (A+B, 3H, t, J = 7.1 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 188.3 (A+B), 163.7 (A), 163.4 (B), 154.6 (A+B), 144.9 (A+B), 119.1 (A+B), 105.9 (A+B), 61.8 (A+B), 51.7 (A), 51.5 (B), 41.3 (A+B), 14.4 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for
C10H12NO4: 210.0761, found 210.0767, error 3.0 ppm.
An alternative preparation of Step 5 where pyrrolidine is used as a solvent and the reaction is run at ambient temperature as a result is presented below:
Step 5: Preparation of ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)- carboxylate (7)
Ethyl 4-oxo-4,5-dihydrofuro[2,3-c]pyridine-6(7H)-carboxylate (6) (1.90 g, 9.07 mmol) was dissolved in pyrrolidine (3 mL, 5 vols.) and stirred for lh at 20°C. 35% aqueous ammonia in water (7ml) was added and stirring continued at 20°C for 4 hours. The mixture was concentrated in vacuo and then the residue was partitioned between ethyl acetate (20ml, 10.5vol) and water (20ml, 10.5vol). The aqueous layer was separated and extracted with ethyl acetate (3 x 20ml, 3 x 10.5vol), then the combined extracts were washed with 0.1M hydrochloric acid (25ml, 13.2vol), and water (25ml, 13.2vol), then dried and concentrated in vacuo to give ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate (7) as a brown oil. 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately equal ratio are visible. They are due to restricted rotation of the tertiary amide: d 11.58 (A, 1H, s), 11.53 (B, 1H, s), 6.87-6.88 (A+B, 1H, m), 6.36 (A+B, 1H, dd, J = 2.2 Hz, 2.8 Hz), 4.70 (A+B, 2H, br s), 4.09 (A+B, 2H, q, J = 7.1 Hz), 4.06 (A+B, 2H, br s), 1.20 (A+B, 3H, t, J = 7.1 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 188.0 (A),
187.8 (B), 155.2 (A), 155.1 (B), 140.9 (A), 140.5 (B), 120.8 (A+B), 118.2 (A), 118.0 (B),
104.9 (A+B), 61.9 (A+B), 52.2 (A), 52.0 (B), 41.1 (A), 41.0 (B), 14.9 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for C10H13N2O3 : 209.0921, found 209.0929, error 3.9 ppm.
Step 8 is the same as for Example 2.
Step 8: Preparation of ethyl 4-oxo-l-tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine- 6(7H)-carboxylate (10)
To a solution of (ethyl 4-oxo-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate) (7) (0.50 g, 2.4 mmol) in methylene chloride (5 mL, 10 vols.) was added triethylamine (0.97 mL, 7.2 mmol, 3 eqv) dropwise at room temperature. To the resulting suspension was added p-toluenesulphonyl chloride (0.46 g, 2.4 mmol, 1 eqv) and 4-dimethylaminopyridine (DMAP) (0.029 g, 0.24 mmol, 0.1 eqv). The reaction mixture was stirred until p-toluenesulphonyl chloride was consumed. The mixture was poured into water (10 mL, 20 vols.) and extracted with methylene chloride (2x 5 mL, 2x 10 vols.)· Combined organic layers were dried over anhydrous magnesium sulphate, filtered and evaporated in vacuo. The crude was purified by flash chromatography on silica gel (10% ethyl acetate in cyclohexane) affording ethyl 4-oxo-l- tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate (10) as a pale pink solid (0.58 g, 2.0 mmol, 83.0% yield). 1H NMR (600 MHz, DMSO-d6, 300K). [Note: at this temperature, two rotamers (A + B) in an approximately equal ratio are visible. They are due to restricted rotation of the tertiary amide: d 7.96 (A+B, 2H, d, J = 8.3 Hz), 7.55-7.53 (A+B, 3H, m), 6.64 (A+B, 1H, d, J = 3.5 Hz), 4.98 (A+B, 2H, s), 4.13 (A+B, 2H, br s), 4.07 (A+B, 2H br q, J =
7.0 Hz), 2.42 (3H, s), 1.17 (A+B, 3H, br t, J = 7.0 Hz). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 189.1 (A), 188.6 (B), 155.2 (A), 155.0 (B), 147.3 (A+B), 141.1 (A), 140.7 (B), 134.3 (A+B), 131.1 (A+B), 127.7 (A+B), 123.9 (A+B), 122.8 (A), 122.6 (B), 108.8 (A+B), 62.3 (A+B), 51.9 (A+B), 41.6 (A), 41.4 (B), 21.6 (A+B), 14.8 (A+B). HRMS (ESI) m/z [M+H}+: molecular ion calculated for C17H19N2O5S: 363.1009, found 363.1017, error 2.2 ppm.
An alternative preparation of Step 9 where tert-butyl hydroperoxide in decane is used as an oxidant is presented below:
Step 9: Preparation of 4-methoxy-l-(4-methylphenylsulphonyl)-lH-pyrrolo[2,3- c]pyridine (11)
(Ethyl 4-oxo-l-tosyl-4,5-dihydro-lH-pyrrolo[2,3-c]pyridine-6(7H)-carboxylate) (10) (2.00 g, 5.52 mmol) and toluene (24ml, 12vol) was charged to reaction vessel then the vessel was inerted using N2. Methane sulphonic acid (0.53 mL, 8.16 mmol, 1.48 eqv,) and trimethylorthoformate (1.83 mL, 16.7 mmol, 3.02 eqv) were added inertion was continued for 3 minutes. Methanol (1.1ml, 27.1mmol, 4.9eqw) and 5.5M tert-butyl hydroperoxide in decane (1.3 mL, 7.15 mmol, 1.3 eqv) were added and the reaction mixture was aged at 35 °C for 18 hours. 2M sodium hydroxide (10ml, 5 vol) and 0.1M sodium thiosulfate (5ml, 2.5vol) were added and the reaction mixture was stirred at 20°C for 2 hours. The phases were separated and the aqueous layer was extracted with ethyl acetate (2 x 25ml, 2 x 12.5vol).
The combined organic solutions were dried over MgSO4 and concentrated in vacuo. The residue was partitioned between 2M hydrochloric acid (10ml, 5 vol) and tert-butylmethylether (10ml, 5 vol). The aqueous layer was separated and neutralised by addition of sodium hydroxide, then extracted with tert-butylmethylether (3 x 10ml, 3 x 5 vol). The combined organic extracts were dried over MgSO4 and concentrated in vacuo to give 4-methoxy-l-(4- methylphenylsulphonyl)-lH-pyrrolo[2,3-c]pyridine (11) (0.91g, 54% th). ). 1H NMR (600 MHz, DMSO-d6, 300K): d 8.88 (1H, br s), 8.12 (1H, br s), 8.06-8.09 (2H, m), 7.96-7.93 (3H, m),
7.41 (2H, d, J = 8.3 Hz), 6.89 (1H, d, J = 3.6 Hz), 3.96 (3H, s), 2.33 (3H, s). 13C{1H} NMR (151 MHz, DMSO-d6, 300K): d 149.2, 146.5, 134.2, 132.5, 130.9, 129.5, 128.8, 127.4, 126.2, 125.5, 105.8, 56.6, 21.5. HRMS (ESI) m/z [M+H}+: molecular ion calculated for C15H15N2O3S: 303.0798, found 303.0808, error 3.2 ppm.
Even though the depicted 5-membered ring in Formula IV contains a Nitrogen atom, we have found that our cost of goods is lower starting with a five-membered ring that contains an Oxygen.

Claims

What is claimed is:
1. A method for the preparation of a compound of Formula IV
wherein P1 is H or a suitable protecting group;
comprising the preparation of a compound of Formula I
wherein P2 is H or a suitable protecting group and R1 is H or C1-6alkyl.
2. The method of Claim 1 further comprising the conversion of a compound of Formula I to a compound of Formula II
wherein each P2 is independently H or a suitable protecting group.
3. The method of Claim 2 further comprising the conversion of a compound of Formula II into a compound of Formula III
wherein each P1 and P2 are independently H or a suitable protecting group.
4. A method according to any of Claims 1-3 wherein R1 is H or Ci-3alkyl.
5. The method of Claim 4 wherein R1 is H or ethyl.
6. A method according to any of Claims 1-5 wherein each P1 is independently H or a sulphonyl group.
7. The method of Claim 6 wherein each P1 is independently H or a mesylate, besylate, or tosylate group.
8. A method according to any of Claims 1-7 wherein each P2 is independently H or an alkyloxycarbonyl, aryloxycarbonyl, acetyl optionally substituted with 1-3 halogens, sulphonyl, alkyl, or benzyl group.
9. The method of Claim 8 wherein each P2 is independently H or -C(0)-0-C1-4alkyl, -C(O)- C1-4alkyl, -C(0)-C1-4haloalkyl, mesylate, besylate, tosylate, C1-6alkyl, or -C1-6alkyl-aryl.
10. A method according to any of Claims 1-9 further comprising the conversion of a compound of Formula IV into Temsavir, Fostemsavir, or a pharmaceutically acceptable salt thereof.
EP20702386.2A 2019-01-17 2020-01-15 Process for preparing fostemsavir Active EP3911651B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962793462P 2019-01-17 2019-01-17
PCT/IB2020/050312 WO2020148679A1 (en) 2019-01-17 2020-01-15 Process for preparing fostemsavir

Publications (2)

Publication Number Publication Date
EP3911651A1 true EP3911651A1 (en) 2021-11-24
EP3911651B1 EP3911651B1 (en) 2024-01-10

Family

ID=69326594

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20702386.2A Active EP3911651B1 (en) 2019-01-17 2020-01-15 Process for preparing fostemsavir

Country Status (5)

Country Link
US (1) US12157753B2 (en)
EP (1) EP3911651B1 (en)
JP (1) JP7429236B2 (en)
ES (1) ES2972293T3 (en)
WO (1) WO2020148679A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750702A (en) 1993-10-27 1998-05-12 Neurogen Corporation Certain pyrrolo pyridine-3-carboxamides; a new class of GABA brain receptor ligands
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
ES2268113T3 (en) 2001-06-15 2007-03-16 F. Hoffmann-La Roche Ag DERIVATIVES OF 4-PIPERAZINYLINDOL WITH AFFECTION TO THE RECEIVER 5-HT6.
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7601715B2 (en) 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
CA2682377A1 (en) 2007-03-30 2008-10-09 Nippon Shinyaku Co., Ltd. Heteroaryl derivatives
DK2670751T3 (en) 2011-01-31 2015-07-20 Bristol Myers Squibb Co PROCEDURES FOR MANUFACTURING HIV BINDING INHIBITOR PRODUCT CONNECTION AND INTERMEDIATES
EA024872B1 (en) 2012-02-08 2016-10-31 Бристол-Майерс Сквибб Компани Methods for the preparation of hiv attachment inhibitor piperazine prodrug compound
CN105669686B (en) 2014-11-19 2018-08-03 上海合全药业股份有限公司 A kind of synthetic method of 6- (tertbutyloxycarbonyl) octahydros furans [2,3-c] Pyridine-4-carboxylic acid
CA2971104A1 (en) 2014-12-18 2016-06-23 ViiV Healthcare UK (No.4) Limited A process for preparing halogenated azaindole compounds using boroxine

Also Published As

Publication number Publication date
JP2022517621A (en) 2022-03-09
WO2020148679A1 (en) 2020-07-23
US20220106341A1 (en) 2022-04-07
US12157753B2 (en) 2024-12-03
ES2972293T3 (en) 2024-06-12
JP7429236B2 (en) 2024-02-07
EP3911651B1 (en) 2024-01-10

Similar Documents

Publication Publication Date Title
KR102078429B1 (en) Synthesis of pyrrolo[2,3-b]-pyridines
EP2410855B1 (en) Process for the preparation of alogliptin
CA2908408C (en) Dihydropyrido pyrimidine compounds as autotaxin inhibitors
PT95655B (en) PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES
CN102329325B (en) Pyrrolopyrimidone dipeptidyl peptidase-IV (DPP-IV) inhibitors
KR20170075713A (en) Method for preparing idelalisib
EP1487450A1 (en) Process for the preparation of antiviral 7-azaindole derivatives
CA2896155A1 (en) Process for the preparation of 1-([1,3]dioxolan-4-ylmethyl)-1h-pyrazol-3-ylamine
CA2996258A1 (en) A process for the preparation of xylene linked cyclam compounds
EP3911651B1 (en) Process for preparing fostemsavir
CN101107228B (en) Process for producing (Z)-1-phenyl-1-(N,N-diethylaminocarbonyl)-2-phthalimidomethylcyclopropane
CN102311447B (en) Heterocyclo pyrimidone dipeptidyl peptidase-IV (DPP-IV) inhibitor
EP1853591B1 (en) Method for obtaining a pharmaceutically active compound (irbesartan) and its synthesis intermediate
CS268189B2 (en) Method of quinazolinediones and pyridopyrimidinodiones production
WO2016115962A1 (en) Preparation method for nebivolol intermediate and preparation method for nebivolol
Ersoy et al. Design and syntheses of three haptens to generate catalytic antibodies that cleave amide bonds with nucleophilic catalysis
KR20230023566A (en) one-pot synthesis Method of 1,3-Disubstitued indolizines
WO2009064210A2 (en) Process
CN104245672B (en) Prepare the method for roflumilast
CN103664943B (en) The Preparation Method And Their Intermediate of purine derivative and application
CN113816955B (en) RET kinase inhibitor intermediate and preparation method thereof
CN104098556A (en) Novel synthetic process for rivaroxaban
FR2865734A1 (en) NOVEL BENZO [b] CHROMENO-NAPHTHYRIDIN-7-ONE AND PYRANO [2'3 ': 7,8] QUINO [2,3-b] QUINOXALIN-7-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN THEM
EP0705266B1 (en) Process for producing imidazole derivative
WO2006134078A1 (en) Method for obtaining benzimidazole derivatives and intermediates thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210726

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220719

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230414

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VIIV HEALTHCARE UK (NO.4) LIMITED

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230519

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20230821

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: VIIV HEALTHCARE UK (NO.4) LIMITED

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602020024162

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20240110

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2972293

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20240612

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1648823

Country of ref document: AT

Kind code of ref document: T

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240410

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240410

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240410

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240411

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240510

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602020024162

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20240131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

26N No opposition filed

Effective date: 20241011

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20200115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20200115

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20240110

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20251217

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20251217

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20260202

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20251217

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20260107

Year of fee payment: 7